Metabolic Dysfunction-Associated Fatty Liver Disease and Liver Function Markers Are Associated with Crohn's Disease but Not Ulcerative Colitis: a Prospective Cohort Study.

Jie Chen,Lintao Dan,Xinru Tu,Yuhao Sun,Minzi Deng,Xuejie Chen,Therese Hesketh,Ran Li,Xiaoyan Wang,Xue Li
DOI: https://doi.org/10.1007/s12072-022-10424-6
IF: 9.029
2022-01-01
Hepatology International
Abstract:Metabolic dysfunction-associated fatty liver disease (MAFLD) is recently recognized as a condition featured with metabolic dysfunctions in liver. It has been supposed that MAFLD might contribute to the development of IBD, but evidence from prospective cohort studies is lacking and inconclusive. A total of 221,546 females and 183,867 males from the UK Biobank cohort enrolled in 2006–2010 were included to examine whether MAFLD and liver function markers were related to incident IBD. MAFLD was identified based on hepatic steatosis defined by fatty liver index plus the prevalence of overweight, type 2 diabetes mellitus, or at least two metabolic abnormalities. Biomarker related to liver function (albumin [ALB], alkaline phosphatase [ALP], alanine transaminase [ALT], aspartate transaminase [AST]; gamma-glutamyl transferase [GGT], total bilirubin [TB], total protein [TP]) was measured using colorimetric or enzymatic assays. The incidence of IBD was ascertained based on primary care and inpatient records. Cox proportional hazard model was used to estimate hazard ratios (HRs) with 95
What problem does this paper attempt to address?